Long-Term Clinical Burden, Treatment Patterns, and Healthcare Utilization in Children with Lennox–Gastaut Syndrome and Infantile Epileptic Spasms Syndrome: A Nationwide Population-Based Claims Study

Article information

Ann Child Neurol. 2026;34(4):288-296
Publication date (electronic) : 2026 September 29
doi : https://doi.org/10.26815/acn.2026.01585
1Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea
2Department of Pediatrics, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Korea
3Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
4Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, Seoul, Korea
Corresponding author: Mi-Sun Yum, MD, PhD Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Tel: +82-2-3010-3386 E-mail: misun.yum@gmail.com
Received 2026 April 14; Revised 2026 July 7; Accepted 2026 August 19.

Abstract

Purpose

Lennox–Gastaut syndrome (LGS) and infantile epileptic spasms syndrome (IESS) are severe developmental epileptic encephalopathies associated with substantial treatment burden and healthcare utilization. This study characterized clinical features, treatment burden, complications, and healthcare utilization in a nationwide cohort of patients with LGS and IESS and examined differences according to clinical severity.

Methods

We retrospectively analyzed patients diagnosed with LGS or IESS between January 2009 and December 2021 using a nationwide insurance claims database. Clinical characteristics, treatment burden, complications, and healthcare utilization were examined according to recorded intellectual disability (ID) and the operational definition of intractable epilepsy.

Results

The analysis included 4,124 patients with LGS or IESS; 64.1% had a recorded diagnosis of ID and 51.2% met the operational definition of intractable epilepsy. The absence of these conditions in some patients' records indicated variability in documented long-term disease burden. Patients with intractable epilepsy had greater treatment burden and healthcare utilization, including the use of more antiseizure medications, more frequent surgical interventions, and higher frequencies of hospitalization, intensive care unit admission, and medical complications. Polypharmacy and healthcare burden increased over time, particularly in these patients.

Conclusion

In this nationwide cohort, children with LGS and IESS had substantial treatment burden and healthcare utilization, with differences according to clinical severity. These findings may inform risk stratification and long-term management.

Introduction

Infantile epileptic spasms syndrome (IESS) and Lennox–Gastaut syndrome (LGS) are representative developmental epileptic encephalopathies. IESS begins in infancy and is broadly defined to include both West syndrome and epileptic spasms [1]; many patients with IESS subsequently progress to LGS [2]. LGS is characterized by multiple types of drug-resistant seizures, cognitive impairment, frequent behavioral impairment, diffuse slow spike-and-wave patterns, and generalized paroxysmal fast activity on electroencephalography (EEG) [3]. Both conditions are rare: reported prevalence ranges from approximately 1.9 to 60.8 per 100,000 people for LGS and is 0.015 per 1,000 people for IESS [4,5]. LGS and IESS share clinical features, including intellectual disability (ID) and intractable epilepsy, as well as etiologic heterogeneity, with both acquired and genetic or congenital causes. Acquired causes include intracranial infection, hypoxic–ischemic encephalopathy, stroke, neonatal hypoglycemia, and autoimmune encephalitis; genetic causes include malformations of cortical development, tuberous sclerosis complex, and Sturge–Weber syndrome [6,7]. Both syndromes generally have poor clinical outcomes: many patients have epilepsy that is not adequately controlled with medication or surgery, and cognitive outcomes are often unfavorable [8,9]. Because of their intractability and substantial comorbidities, IESS and LGS are associated with markedly greater healthcare utilization than that of the general population, resulting in considerable economic burden and caregiver stress [10-14].

Because these diseases are rare, most studies of LGS and IESS have been conducted in small patient populations [15]. Although some insurance claims studies have included larger patient cohorts, most have been limited to economic burden or general epidemiology or have focused on restricted population groups rather than comprehensive long-term clinical characterization [12,16,17].

South Korea operates a single, mandatory National Health Insurance Service that provides near-complete coverage of the entire population. All reimbursed medical services are reviewed and recorded by the Health Insurance Review and Assessment Service (HIRA), resulting in a comprehensive nationwide claims database. This system enables large-scale, population-based observational research with long-term follow-up across a single healthcare system, thereby minimizing selection bias and loss to follow-up and providing sufficient statistical power to investigate rare diseases with very low incidence rates, including LGS and IESS.

The purpose of this study was to use Korean national insurance claims data to comprehensively investigate the epidemiology, clinical characteristics, treatment patterns, long-term seizure and developmental outcomes, healthcare utilization, and complications of patients with LGS and IESS. Beyond describing the overall disease burden, we aimed to examine differences in long-term outcomes and treatment burden within this population, including patients with relatively low documented seizure burden and healthcare utilization despite the traditionally severe nature of these syndromes. We also evaluated how the presence of intractable epilepsy was associated with long-term outcomes and healthcare utilization, with the goal of informing risk stratification and more individualized long-term management strategies.

Materials and Methods

1. Dataset and patient selection

This study used HIRA claims submitted between January 1, 2007, and December 31, 2021. We identified children newly diagnosed before 18 years of age with code G40.4x from the International Classification of Diseases, 10th Revision (ICD-10). Because EEG findings and detailed seizure semiology are unavailable in the HIRA database, syndrome classification was based on an operational definition using administrative codes.

Given the chronic nature of LGS and IESS, which require ongoing medical care and long-term antiseizure medication (ASM) use, we applied a 2-year washout period (2007–2008) to reduce misclassification of prevalent cases as incident cases. By excluding individuals with prior diagnosis or treatment records during the washout period, we sought to ensure that cases identified during the study period were more likely to represent newly diagnosed LGS or IESS, consistent with standard approaches in claims-based epidemiologic studies [18]. Because developmental diagnoses such as ID are often established after early childhood, we included only patients followed beyond 6 years of age to reduce bias from incomplete ascertainment.

2. Outcomes and confounding variables

HIRA data include patient demographic information, ICD-10 diagnosis codes, and treatment codes covering medical services and medication prescriptions (Supplementary Table 1). Study outcome data were extracted using the relevant diagnosis and treatment codes. Age at first diagnosis was defined as the patient's age when the G40.4x code was first recorded in the claims database.

Etiologies, complications, and comorbidities were identified from ICD-10 codes, with one recorded claim considered sufficient for ascertainment. For acquired etiologies, including brain hemorrhage, hypoxic brain injury, central nervous system infection, traumatic brain injury, and intracranial tumor, the corresponding code had to precede the initial G40.4x diagnosis. By contrast, congenital or underlying etiologies, including metabolic or genetic disorders and structural brain abnormalities, were identified from codes recorded at any time during available follow-up because these conditions may be diagnosed after epilepsy onset in claims data. Neurodevelopmental comorbidities, including ID and autism spectrum disorder (ASD), and status epilepticus were also defined by one recorded ICD-10 code. Complications, including pneumonia, dislocation, pressure ulcer, and osteoporotic fracture, were counted only when the corresponding code was recorded within 5 years after the initial G40.4x diagnosis.

Etiologies were classified as structural, metabolic or genetic, infectious, or unknown. Neurodevelopmental conditions, including ID and ASD, were analyzed as comorbidities rather than etiologic categories.

Because ICD-10 code G40.4 does not distinguish IESS from LGS and electroclinical and EEG data were unavailable, we used age at first G40.4x coding as an operational classification criterion. The criterion was guided by the International League Against Epilepsy (ILAE) classification [1], which describes IESS as beginning in infancy, typically within the first 24 months of life, whereas LGS generally emerges later in childhood. Patients first coded at ≤2 years of age were therefore classified as having IESS, and those first coded at >2 years were classified as having LGS. Based on this stratification, we analyzed patterns of ASM use for each syndrome. ASM use was identified from drug codes for the active ingredients. Information on emergency department visits, intensive care unit (ICU) admissions, and general ward admissions was obtained from the corresponding treatment codes. Data on gastrostomy, tracheostomy, jejunostomy, nasogastric tube insertion, epilepsy surgery, vagus nerve stimulation (VNS), and deep brain stimulation (DBS) were also collected using the corresponding treatment codes. Intractable epilepsy was operationally defined as epilepsy (G40.x) treated with three or more ASMs simultaneously for more than 6 months or with epilepsy surgery. This operational definition was informed by the ILAE definition of drug-resistant epilepsy, which requires inadequate seizure control despite appropriate trials of two or more ASMs [19]. The ICD-10 diagnosis codes and treatment codes for emergency department visits and ICU admissions are provided in Supplementary Tables 2-4. Definitions used combinations of diagnosis and treatment codes to improve specificity where applicable.

3. Statistical analysis

Baseline characteristics were compared between groups using standardized mean differences (SMDs), with an absolute SMD <0.1 indicating a negligible difference. Continuous data are presented as means with standard deviations or confidence intervals, as applicable. Given the descriptive and exploratory nature of this claims-based study, the analyses used unadjusted comparisons between predefined clinical subgroups. All statistical analyses were performed with SAS Enterprise Guide version 7.1 (SAS Institute Inc., Cary, NC, USA).

4. Ethical approval

The Institutional Review Board of Asan Medical Center approved this study (IRB No. 2023-0695). In addition, the data provided by HIRA were fully anonymized. The requirement for written informed consent was waived because of the retrospective nature of the study.

Results

1. Overall patient characteristics and neurodevelopmental outcomes in the cohort

During the study period, 4,124 patients were coded with G40.4x. Of these, 2,390 (58.0%) were male. Mean age at initial diagnosis was 4.7 years, and mean follow-up was 8.3 years. Using the operational definition of coding at ≤2 years of age for IESS, 1,263 patients (30.6%) were classified as having IESS and 2,861 (69.4%) as having LGS (Fig. 1). Mean age at initial diagnosis was 0.5 years for IESS and 6.5 years for LGS. Based on the average pediatric population of 8,700,897 from 2009 to 2021, the calculated incidence rates were 2.53 per 100,000 for LGS and 1.11 per 100,000 for IESS.

Fig. 1.

Age distribution of Lennox–Gastaut syndrome (LGS) and infantile epileptic spasms syndrome (IESS).

Etiology was unknown in 2,161 patients (52.4%). The most common identified etiology was a structural abnormality in 884 patients (21.4%), followed by a metabolic or genetic etiology in 873 patients (21.2%) and central nervous system infection in 206 patients (5%) (Table 1). Analysis of age at first diagnosis by etiology showed similar mean ages among the identified-etiology groups: 2.6 years for metabolic or genetic etiologies, 2.7 years for structural etiologies, and 3.1 years for infectious etiologies. By contrast, mean age at first diagnosis was 6.3 years for unknown etiology, indicating that patients with an identified etiology were coded earlier in the claims database. The etiologic distributions also differed between the operational IESS and LGS groups. Structural etiologies were recorded in 30.6% of IESS cases compared with 17.4% of LGS cases. Metabolic or genetic etiologies were recorded in 28.3% and 18.0%, respectively, and infectious etiologies in 3.4% and 5.7%, respectively. Etiology remained unknown in 37.6% of IESS cases and 58.9% of LGS cases.

Etiologies of patients with IESS and LGS

Among all patients, 2,645 (64.1%) had a recorded diagnosis of ID, 2,111 (51.2%) met the operational definition of intractable epilepsy, 931 (22.6%) had a recorded diagnosis of ASD, and 29 (0.7%) had status epilepticus (Fig. 2). The ID, ASD, and intractable-epilepsy groups overlapped substantially: 505 patients (12.2%) had all three conditions, whereas 942 (22.8%) had none of the three recorded conditions.

Fig. 2.

Comorbidities and intractable epilepsy outcomes at last follow-up.

2. Epilepsy treatments and patients with intractable seizures during the follow-up period

Patients received a mean of 5.1 distinct ASMs during follow-up and were receiving a mean of 3.1 ASMs at the last follow-up (Table 2). When ASM use was analyzed over the 10 years after the initial diagnosis, approximately 70% of patients classified as having IESS initially received vigabatrin. This proportion decreased over time to less than 20% at 10 years, whereas the proportions receiving other ASMs increased (Fig. 3A). More than 40% received steroids (methylprednisolone or prednisolone) at the time of initial diagnosis. Among patients classified as having LGS, the use of lamotrigine, clobazam, and rufinamide gradually increased over time after the initial diagnosis (Fig. 3B and D); the use of valproate and carbamazepine decreased slightly; and the use of oxcarbazepine remained relatively stable. In addition, a small but increasing proportion received cannabidiol. Among patients classified as having IESS, approximately 7% received rufinamide over time after diagnosis, whereas fewer than 5% received prescriptions for cannabidiol (Fig. 3C and D). At diagnosis, approximately 20% of patients were receiving three or more ASMs. This proportion increased over time, and more than one-third were receiving three or more ASMs 10 years after diagnosis (Fig. 4). Regarding surgical treatment, 233 patients underwent epilepsy surgery, 258 received VNS, and five received DBS.

Comparison of supportive interventions, healthcare resource utilization, and epilepsy management, including ASMs, between patients with and without intractable epilepsy

Fig. 3.

Changes in the use of antiseizure medications after the initial diagnosis (in 6-month intervals). (A) Infantile epileptic spasms syndrome (IESS), (B) Lennox–Gastaut syndrome (LGS), (C) rufinamide and cannabidiol in IESS, and (D) IESS+LGS.

Fig. 4.

Longitudinal changes in the number of patients receiving fewer than three versus three or more antiseizure medications (ASMs) after diagnosis.

3. Complications and healthcare resource utilization

A total of 132 patients underwent gastrostomy, 39 patients underwent tracheostomy, and 462 patients received feeding through nasogastric tubes. Analysis of claims recorded within 5 years after the initial diagnosis showed that 6.5% of all patients had a recorded osteoporotic fracture and 14.8% had a recorded dislocation (Table 2). In addition, 69.3% had a recorded diagnosis of pneumonia, and 7.8% had a recorded pressure ulcer within 5 years. Within 5 years after the initial diagnosis, 77.9% of patients had visited the emergency department, with a mean of 5.9 visits among these patients (Table 2). A total of 23.1% of patients were admitted to the ICU, with a mean of 2.0 admissions among those admitted, and 97.2% were admitted to the general ward, with a mean of 19.9 admissions among these patients.

4. Comparisons between those with or without intractable epilepsy

Patients with intractable epilepsy received a greater number of distinct ASMs during follow-up than those without intractable epilepsy (7.4 vs. 2.6; SMD, 1.23). At the last follow-up visit, the number of concurrent ASMs was also higher among patients with intractable epilepsy than among those without intractable epilepsy (4.4 vs. 1.6; SMD, 1.30). Patients with intractable epilepsy had higher proportions of all four recorded complications than those without intractable epilepsy: 7.9% vs. 5.0% for osteoporotic fracture, 17.1% vs. 12.3% for dislocation, 77.9% vs. 60.3% for pneumonia, and 9.9% vs. 5.7% for pressure ulcer. There were also differences in healthcare resource utilization between the two groups. Within 5 years after diagnosis, patients with intractable epilepsy more often visited the emergency department (82.0% vs. 73.6%) and were admitted to the ICU (28.5% vs. 17.4%). Although a slightly smaller proportion of patients with intractable epilepsy were admitted to general wards, the number of admissions per patient was higher in this group (24.1 vs. 10.3) (Table 2).

Discussion

This study represents the first nationwide, population-based analysis of LGS and IESS conducted in South Korea. Previous studies of these two conditions in South Korea were predominantly single-center investigations or evaluations of specific pharmacologic or surgical treatment outcomes and lacked long-term follow-up data [15,20]. A study of IESS conducted in 2001, which focused on patients diagnosed with West syndrome at that time, analyzed data from 21 hospitals across South Korea for the period from 1997 to 2000 [21]. However, the study was cross-sectional, was based on a national survey, included fewer patients than the present study, and did not provide long-term follow-up data.

In our nationwide cohort, the estimated incidence rates of LGS and IESS were comparable to those reported in previous population-based studies in Korea and other regions [21,22]. The consistency of these incidence estimates supports the overall reliability of case ascertainment and demographic data in this study. Males slightly outnumbered females among patients with LGS and IESS. Although this observation has not been reported consistently in the literature, it has been documented in some studies [23,24]. Mean age at first diagnosis was 6.5 years for LGS and 0.5 years for IESS. These distributions are consistent with previous reports describing IESS as beginning in infancy, with peak onset at 3–7 months, and LGS as predominantly beginning in childhood, with most diagnoses between early and middle childhood—particularly at 5–10 years—although diagnoses in adolescence have also been reported [5,25].

Because LGS and IESS encompass a broad range of underlying etiologies, we examined the distribution of etiologic categories and their relationship with age at first diagnosis. Etiology was unknown in more than half of the cohort, consistent with studies reporting that approximately 40% to 50% of LGS and IESS cases lack an identifiable cause [6]. Among patients with an identified etiology, structural and metabolic or genetic causes occurred in similar proportions.

Age at first diagnosis analyses showed a clear difference between patients with known and unknown etiologies. Patients with metabolic or genetic, structural, or infectious etiologies were coded earlier (mean, 2.6 to 3.1 years) than those with unknown etiology (mean, 6.3 years), suggesting that identifiable etiologic factors were more strongly associated with earlier coding. This pattern was also reflected in syndrome-specific differences: IESS had higher proportions of structural and metabolic or genetic etiologies and a lower proportion of unknown etiology, whereas unknown etiology predominated in LGS.

These findings are consistent with reports that IESS is more often associated with early brain insults or defined etiologies, whereas LGS is more heterogeneous and includes a substantial proportion of cases without an identifiable cause [26]. The relatively high proportion of unknown etiology in this cohort may partly reflect the long study period, much of which preceded widespread advanced genetic testing [27].

Because this study used long-term claims data covering the entire nationwide population, our primary focus was the assessment of disease burden and treatment patterns. Accordingly, we examined factors such as recorded ASD or ID diagnoses, medication use, hospitalization rates, and complications. Comorbidities such as ASD, ID, and intractable epilepsy were frequently recorded among patients with LGS or IESS. In LGS, the coexistence of intractable seizures and ID is expected given the nature of the disease and has been documented in previous studies [15,28]. Similarly, a follow-up study of 214 patients with infantile spasms found that 13% had ASD and 76% had poor intellectual outcomes, defined as intelligence quotient scores below 68 [29]. In our cohort, approximately one-third of patients had no recorded diagnosis of ID or ASD, a proportion higher than that reported in previous studies of LGS and IESS [8,9]. This finding highlights the clinical variability of IESS and LGS while also raising the possibility that ID or ASD was underascertained, potentially because of social stigma or other factors influencing diagnostic practices.

Importantly, a subset of patients had no recorded diagnosis of ID or intractable epilepsy during follow-up. This observation suggests that the documented long-term disease burden and trajectories of patients classified as having LGS or IESS were not uniform and highlights meaningful variability within the cohort.

Although the overall prognosis of LGS and IESS is generally poor, about 50% of patients in our cohort achieved relatively good seizure control during follow-up. We therefore compared disease burden according to the presence of intractable epilepsy. Patients with intractable epilepsy had greater healthcare utilization, more frequent complications, and higher treatment demands. These findings identify intractable epilepsy as an important marker of long-term disease burden in patients with LGS and IESS [30].

ASMs play a central role in the management of LGS and IESS. Previous guidelines recommend valproate and clobazam as first-line ASMs for LGS, with lamotrigine, topiramate, and felbamate as second-line options, followed by rufinamide and cannabidiol as subsequent options. For IESS, steroids, including adrenocorticotropic hormone or methylprednisolone/prednisolone, and vigabatrin are recommended as first-line treatments, with topiramate, valproate, zonisamide, and benzodiazepines as additional treatment options [31-33]. Compared with these general guidelines, oxcarbazepine and carbamazepine were prescribed relatively frequently to patients classified as having LGS, whereas phenobarbital and levetiracetam were prescribed relatively frequently to those classified as having IESS. We also observed that steroids were prescribed long after the initial diagnosis, possibly because they are frequently used in primary care settings for respiratory infections. Although the exact proportion of patients transitioning from IESS to LGS could not be determined, we used prescriptions for rufinamide and cannabidiol as an indirect indicator of possible transition. In the Korean National Health Insurance reimbursement system, these medications are reimbursed almost exclusively for patients diagnosed with LGS; their prescription therefore served as a proxy for an LGS diagnosis in this claims-based dataset. Over long-term follow-up, the overall number of patients under observation decreased, whereas the proportion receiving three or more ASMs increased. These patterns suggest poor long-term outcomes despite available seizure-management approaches, including dietary therapies, epilepsy surgery, and the introduction of newer ASMs. For patients with LGS, neuromodulation therapies such as VNS and DBS are recommended for drug-resistant seizures, yet these interventions were infrequently used in Korea despite guideline support [34,35]. By contrast, supportive procedures such as gastrostomy and tracheostomy were used more frequently, particularly among patients with ID or intractable epilepsy, reflecting substantial long-term care needs among patients with severe LGS and IESS. Together, these findings suggest a gap between recommended seizure-directed interventions and the high level of supportive care required in real-world clinical practice.

This study has several limitations. First, mortality data were unavailable in the HIRA database and could not be analyzed. Second, because this was a claims-based study, syndrome identification relied on ICD-10 codes and an age-based operational definition rather than detailed electroclinical features, seizure semiology, or EEG findings. In particular, ICD-10 code G40.4x is not specific to LGS or IESS and may include other generalized epilepsy syndromes, such as epilepsy with myoclonic absences or epilepsy with myoclonic-atonic seizures. The age-based classification of IESS and LGS has not been formally validated against clinical diagnoses or EEG findings; therefore, population misclassification cannot be excluded. Direct identification of transition from IESS to LGS was also infeasible in this claims database because the two syndromes share the same ICD-10 code in the Korean claims system. Third, etiologies, complications, and comorbidities were identified from one recorded ICD-10 code rather than from repeated or inpatient claims. Although this approach may improve sensitivity in a nationwide claims-based study, it may reduce diagnostic specificity and lead to misclassification. Fourth, developmental diagnoses such as ID may be incompletely ascertained in patients with shorter follow-up periods. We sought to reduce this potential bias by restricting the analysis to patients followed beyond 6 years of age.

Nevertheless, age-at-diagnosis distributions and syndrome-consistent medication trajectories provided indirect support for the expected disease course: patients coded in infancy predominantly received IESS-related therapies, whereas patients coded later increasingly received LGS-specific medications. However, the primary aim of this study was not to quantify transition rates but rather to characterize long-term disease burden, treatment patterns, and healthcare utilization at the population level.

Despite these limitations, this nationwide cohort provides population-level evidence on the long-term clinical burden and healthcare utilization of children with LGS and IESS and offers insight into the real-world burden of developmental epileptic encephalopathies.

In this nationwide population-based study, we characterized the clinical features, treatment burden, complications, and healthcare utilization of children with LGS and IESS. Patients with greater clinical severity had higher treatment burden and healthcare utilization, underscoring the importance of long-term monitoring and individualized long-term clinical management. These population-level findings may support clinical decision-making and long-term care planning.

Supplementary material

Supplementary materials related to this article can be found online at https://doi.org/10.26815/acn.2026.01585

Supplementary Table 1.

Antiseizure medications used in the analysis

acn-2026-01585-Supplementary-Table-1.pdf
Supplementary Table 2.

ICD-10 codes for etiology

acn-2026-01585-Supplementary-Table-2.pdf
Supplementary Table 3.

ICD-10 codes for complication and comorbidity

acn-2026-01585-Supplementary-Table-3.pdf
Supplementary Table 4.

Treatment codes for emergency room visits, intensive care unit admissions

acn-2026-01585-Supplementary-Table-4.pdf

Notes

Conflicts of interest

Tae-Sung Ko is an editorial board member of the journal, but he was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Author contribution

Conceptualization: YSN, MJK, TSK, EAK, HJK, and MSY. Data curation: OK, MJK, HJK, and MSY. Formal analysis: YSN. Funding acquisition: MSY. Methodology: YSN, OK, MJK, TSK, EAK, HJK, and MSY. Project administration: MSY. Visualization: YSN. Writing - original draft: YSN. Writing - review & editing: HJK and MSY.

Acknowledgments

This research was supported by a grant from the Patient-Centered Clinical Research Coordinating Center (PACEN), funded by the Ministry of Health & Welfare, Republic of Korea (grant No. RS-2020-KH096139).

This study used claims data from HIRA, which can be accessed only through a designated virtual computer with permission from the institution. Therefore, the raw data are not publicly accessible.

References

1. Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions. Epilepsia 2022;63:1349–97. 10.1111/epi.17239. 35503712.
2. You SJ, Kim HD, Kang HC. Factors influencing the evolution of West syndrome to Lennox-Gastaut syndrome. Pediatr Neurol 2009;41:111–3. 10.1016/j.pediatrneurol.2009.03.006. 19589458.
3. Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions. Epilepsia 2022;63:1398–442. 10.1111/epi.17241. 35503717.
4. Jia JL, Chen S, Sivarajah V, Stephens D, Cortez MA. Latitudinal differences on the global epidemiology of infantile spasms: systematic review and meta-analysis. Orphanet J Rare Dis 2018;13:216. 10.1186/s13023-018-0952-x.
5. Sullivan J, Benitez A, Roth J, Andrews JS, Shah D, Butcher E, et al. A systematic literature review on the global epidemiology of Dravet syndrome and Lennox-Gastaut syndrome: prevalence, incidence, diagnosis, and mortality. Epilepsia 2024;65:1240–63. 10.1111/epi.17866.
6. Zhou Z, Jiao X, Gong P, Niu Y, Xu Z, Zhang G, et al. Clinical features and underlying etiology of children with Lennox-Gastaut syndrome. J Neurol 2024;271:5392–401. 10.1007/s00415-024-12465-3. 39008035.
7. Wirrell EC, Shellhaas RA, Joshi C, Keator C, Kumar S, Mitchell WG, et al. How should children with West syndrome be efficiently and accurately investigated?: results from the National Infantile Spasms Consortium. Epilepsia 2015;56:617–25. 10.1111/epi.12951. 25779538.
8. Bhanudeep S, Madaan P, Sankhyan N, Saini L, Malhi P, Suthar R, et al. Long-term epilepsy control, motor function, cognition, sleep and quality of life in children with West syndrome. Epilepsy Res 2021;173:106629. 10.1016/j.eplepsyres.2021.106629. 33862315.
9. Vignoli A, Oggioni G, De Maria G, Peron A, Savini MN, Zambrelli E, et al. Lennox-Gastaut syndrome in adulthood: long-term clinical follow-up of 38 patients and analysis of their recorded seizures. Epilepsy Behav 2017;77:73–8. 10.1016/j.yebeh.2017.09.006. 29126048.
10. Cross JH, Benitez A, Roth J, Andrews JS, Shah D, Butcher E, et al. A comprehensive systematic literature review of the burden of illness of Lennox-Gastaut syndrome on patients, caregivers, and society. Epilepsia 2024;65:1224–39. 10.1111/epi.17932. 38456647.
11. Chin RF, Pickrell WO, Guelfucci F, Martin M, Holland R. Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study. Seizure 2021;91:159–66. 10.1016/j.seizure.2021.05.025. 34161904.
12. Reaven NL, Funk SE, Montouris GD, Saurer TB, Story TJ. Burden of illness in patients with possible Lennox-Gastaut syndrome: a retrospective claims-based study. Epilepsy Behav 2018;88:66–73. 10.1016/j.yebeh.2018.08.032. 30241056.
13. Harini C, Yuskaitis CJ, Singh A, McHugh T, Liu S, DeLeo M, et al. Hospital readmissions in children with new-onset infantile epileptic spasms syndrome. Epilepsia Open 2023;8:444–55. 10.1002/epi4.12711. 36790214.
14. Min JY, Knupp KG, Patel AD, Shellhaas RA, Zhang M, Grinspan ZM. Medication selection, health services outcomes, and cost trajectories for Medicaid beneficiaries with infantile spasms. Epilepsy Res 2021;176:106733. 10.1016/j.eplepsyres.2021.106733. 34333373.
15. Kim HJ, Kim HD, Lee JS, Heo K, Kim DS, Kang HC. Long-term prognosis of patients with Lennox-Gastaut syndrome in recent decades. Epilepsy Res 2015;110:10–9. 10.1016/j.eplepsyres.2014.11.004.
16. Strzelczyk A, Schubert-Bast S, Simon A, Wyatt G, Holland R, Rosenow F. Epidemiology, healthcare resource use, and mortality in patients with probable Lennox-Gastaut syndrome: a population-based study on German health insurance data. Epilepsy Behav 2021;115:107647. 10.1016/j.yebeh.2020.107647.
17. Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, et al. Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome. Epilepsy Behav 2017;73:46–50. 10.1016/j.yebeh.2017.05.021.
18. Hwang S, Lim DH, Chung TY. Prevalence and incidence of keratoconus in South Korea: a nationwide population-based study. Am J Ophthalmol 2018;192:56–64. 10.1016/j.ajo.2018.04.027. 29750946.
19. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069–77. 10.1111/j.1528-1167.2009.02397.x. 19889013.
20. Koo CM, Kim SH, Lee JS, Park BJ, Lee HK, Kim HD, et al. Cannabidiol for treating Lennox-Gastaut syndrome and Dravet syndrome in Korea. J Korean Med Sci 2020;35e427. 10.3346/jkms.2020.35.e427. 33372424.
21. Hwang YS, ; Korean Child Neurology Society. National survey on West syndrome in Korea. Brain Dev 2001;23:565–9. 10.1016/s0387-7604(01)00265-0. 11701256.
22. Rantala H, Putkonen T. Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut syndrome. Epilepsia 1999;40:286–9. 10.1111/j.1528-1157.1999.tb00705.x. 10080506.
23. Pavone P, Polizzi A, Marino SD, Corsello G, Falsaperla R, Marino S, et al. West syndrome: a comprehensive review. Neurol Sci 2020;41:3547–62. 10.1007/s10072-020-04600-5. 32827285.
24. Widdess-Walsh P, Dlugos D, Fahlstrom R, Joshi S, Shellhaas R, Boro A, et al. Lennox-Gastaut syndrome of unknown cause: phenotypic characteristics of patients in the Epilepsy Phenome/Genome Project. Epilepsia 2013;54:1898–904. 10.1111/epi.12395. 24116958.
25. Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, et al. Infantile spasms: a U.S. consensus report. Epilepsia 2010;51:2175–89. 10.1111/j.1528-1167.2010.02657.x. 20608959.
26. Smith MS, Matthews R, Rajnik M, Mukherji P. Infantile epileptic spasms syndrome (West syndrome). In: StatPearls. Treasure Island: StatPearls Publishing; 2024. [cited 2026 Sep 4]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537251.
27. Snyder HE, Jain P, Ramachandran Nair R, Jones KC, Whitney R. Genetic advancements in infantile epileptic spasms syndrome and opportunities for precision medicine. Genes (Basel) 2024;15:266. 10.3390/genes15030266. 38540325.
28. Yagi K. Evolution of Lennox-Gastaut syndrome: a long-term longitudinal study. Epilepsia 1996;37 Suppl 3:48–51. 10.1111/j.1528-1157.1996.tb01821.x. 8681913.
29. Riikonen R. Infantile spasms: outcome in clinical studies. Pediatr Neurol 2020;108:54–64. 10.1016/j.pediatrneurol.2020.01.015. 32305143.
30. McGrother CW, Bhaumik S, Thorp CF, Hauck A, Branford D, Watson JM. Epilepsy in adults with intellectual disabilities: prevalence, associations and service implications. Seizure 2006;15:376–86. 10.1016/j.seizure.2006.04.002.
31. Nelson JA, Knupp KG. Lennox-Gastaut syndrome: current treatments, novel therapeutics, and future directions. Neurotherapeutics 2023;20:1255–62. 10.1007/s13311-023-01397-x. 37353676.
32. Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for Lennox-Gastaut syndrome: current and future strategies. CNS Drugs 2021;35:61–83. 10.1007/s40263-020-00784-8.
33. Ramantani G, Bolsterli BK, Alber M, Klepper J, Korinthenberg R, Kurlemann G, et al. Treatment of infantile spasm syndrome: update from the Interdisciplinary Guideline Committee coordinated by the German-Speaking Society of Neuropediatrics. Neuropediatrics 2022;53:389–401. 10.1055/a-1909-2977.
34. Morris GL III, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;81:1453–9. 10.1212/wnl.0b013e3182a393d1.
35. Dalic LJ, Warren AEL, Bulluss KJ, Thevathasan W, Roten A, Churilov L, et al. DBS of thalamic centromedian nucleus for Lennox-Gastaut syndrome (ESTEL Trial). Ann Neurol 2022;91:253–67. 10.1002/ana.26280.

Article information Continued

Fig. 1.

Age distribution of Lennox–Gastaut syndrome (LGS) and infantile epileptic spasms syndrome (IESS).

Fig. 2.

Comorbidities and intractable epilepsy outcomes at last follow-up.

Fig. 3.

Changes in the use of antiseizure medications after the initial diagnosis (in 6-month intervals). (A) Infantile epileptic spasms syndrome (IESS), (B) Lennox–Gastaut syndrome (LGS), (C) rufinamide and cannabidiol in IESS, and (D) IESS+LGS.

Fig. 4.

Longitudinal changes in the number of patients receiving fewer than three versus three or more antiseizure medications (ASMs) after diagnosis.

Table 1.

Etiologies of patients with IESS and LGS

Total (n=4,124)a IESS (n=1,263) LGS (n=2,861) SMD
Structural 884 (21.4) 387 (30.6) 497 (17.4) 0.31
 Brain anomaly 369 (8.9)
 Hypoxic brain injury 200 (4.8)
 Brain hemorrhage 181 (4.4)
 Intracranial tumor 75 (1.8)
 Traumatic brain injury 59 (1.4)
Metabolic/genetic 873 (21.2) 358 (28.3) 515 (18.0) 0.25
 Metabolic disorders 434 (10.5)
 Genetic etiology 318 (7.7)
 Tuberous sclerosis complex 115 (2.8)
 Sturge–Weber syndrome 6 (0.1)
Infectious 206 (5.0) 43 (3.4) 163 (5.7) –0.11
Unknown 2,161 (52.4) 475 (37.6) 1,686 (58.9) –0.44

Values are presented as number (%).

IESS, infantile epileptic spasms syndrome; LGS, Lennox–Gastaut syndrome; SMD, standardized mean difference.

a

Subcategory values are presented for the overall cohort only.

Table 2.

Comparison of supportive interventions, healthcare resource utilization, and epilepsy management, including ASMs, between patients with and without intractable epilepsy

Total (n=4,124) Patients without intractable epilepsy (n=2,013) Patients with intractable epilepsy (n=2,111) SMD
ASM
 Total no. of ASM types prescribed 5.1 (5.00–5.20) 2.6 (2.49–2.71) 7.4 (7.09–7.71) 1.23
 No. of ASMs at last follow-up 3.1 (3.05–3.15) 1.6 (1.53–1.67) 4.4 (4.21–4.59) 1.30
Patients with recorded complications
 Osteoporotic fracture 267 (6.5) 100 (5.0) 167 (7.9) -0.12
 Dislocation 609 (14.8) 247 (12.3) 362 (17.1) -0.14
 Pneumonia 2,858 (69.3) 1,214 (60.3) 1,644 (77.9) -0.39
 Pressure ulcer 323 (7.8) 114 (5.7) 209 (9.9) -0.15
Supportive measures for comorbid conditions
 Gastrostomy 132 (3.2) 20 (1.0) 112 (5.3) -0.25
 Tracheostomy 39 (0.9) 4 (0.2) 35 (1.7) -0.18
 Tube feeding 462 (11.2) 45 (2.2) 417 (19.8) -0.52
Healthcare resource utilization
 Emergency department visits
  Patients 3,214 (77.9) 1,482 (73.6) 1,732 (82.0) -0.20
  Visits per patient 5.9±6.8 5.3±4.9 6.7±6.4 0.25
 Intensive care unit admissions
  Patients 953 (23.1) 351 (17.4) 602 (28.5) -0.27
  Admissions per patient 2.0±3.1 2.3±1.9 2.0±1.8 -0.16
 General ward admissions
  Patients 4,008 (97.2) 1,985 (98.6) 2,023 (95.8) 0.17
  Admissions per patient 19.9±20.1 10.3±11.5 24.1±25.4 0.70

Values are presented as mean (95% confidence interval), number (%), or mean±standard deviation.

ASM, antiseizure medication; SMD, standardized mean difference.